MX2015001788A - Metabolitos de metionina predicen la evolución agresiva del cáncer. - Google Patents

Metabolitos de metionina predicen la evolución agresiva del cáncer.

Info

Publication number
MX2015001788A
MX2015001788A MX2015001788A MX2015001788A MX2015001788A MX 2015001788 A MX2015001788 A MX 2015001788A MX 2015001788 A MX2015001788 A MX 2015001788A MX 2015001788 A MX2015001788 A MX 2015001788A MX 2015001788 A MX2015001788 A MX 2015001788A
Authority
MX
Mexico
Prior art keywords
systems
methods
subject
level
recurrence
Prior art date
Application number
MX2015001788A
Other languages
English (en)
Inventor
Neil A Bhowmick
Diptiman Choudhury
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2015001788A publication Critical patent/MX2015001788A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se refiere al uso de enzimas, nanobarras y dispositivos nanoeléctronicos para detectar el nivel de cisteína en una muestra de un paciente y se refiere al uso del nivel de cisteina detectado para predecir la reaparición de cáncer en el paciente y para indicar y/o administrar una terapia adecuada a un sujeto. La invención se refiere a sistemas y métodos para detectar el nivel de cisteina en una muestra de un sujeto, donde los sistemas o métodos también pueden comprender medir al menos un parámetro adicional, tal como nivel de PSA, puntuación de Gleason y etapa clínica. La invención se refiere a sistemas y métodos para predecir la probabilidad de reaparición de un cáncer en un sujeto, donde los sistemas o métodos también pueden comprender medir al menos un parámetro adicional, tal como nivel de PSA, puntuación de Gleason y etapa clínica. La invención comprende además indicar y/o administrar una terapia adecuada a un sujeto en función de la probabilidad prevista de reaparición.
MX2015001788A 2012-08-10 2013-08-09 Metabolitos de metionina predicen la evolución agresiva del cáncer. MX2015001788A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682155P 2012-08-10 2012-08-10
PCT/US2013/054415 WO2014026157A2 (en) 2012-08-10 2013-08-09 Methionine metabolites predict aggressive cancer progression

Publications (1)

Publication Number Publication Date
MX2015001788A true MX2015001788A (es) 2015-09-28

Family

ID=50066469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001788A MX2015001788A (es) 2012-08-10 2013-08-09 Metabolitos de metionina predicen la evolución agresiva del cáncer.

Country Status (6)

Country Link
US (1) US20140045193A1 (es)
EP (1) EP2882862A4 (es)
AU (1) AU2013299409A1 (es)
CA (1) CA2880928A1 (es)
MX (1) MX2015001788A (es)
WO (1) WO2014026157A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975895A1 (en) * 2015-02-12 2016-08-18 Cedars-Sinai Medical Center Device, system and method for cancer prognosis and uses thereof
CZ306945B6 (cs) * 2015-04-23 2017-10-04 Smart Brain s.r.o. 14-Merkaptotetradecyl-trimethylammonium-bromid, vhodný jako surfaktant pro zlaté nanotyčinky
CN109146335B (zh) * 2018-10-10 2021-08-20 华北电力科学研究院有限责任公司 判断10kV线路电能表系统变比与实际变比一致性的方法
CN110849815B (zh) * 2019-12-02 2022-10-18 中国工程物理研究院激光聚变研究中心 一种预测光学元件表面激光损伤性能的方法和系统
JP2023533959A (ja) * 2020-07-08 2023-08-07 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 前立腺がんの検出及び治療方法
WO2022087593A1 (en) * 2020-10-20 2022-04-28 Baylor College Of Medicine Multiplex metabolic markers in plasma for early detection of african american prostrate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940658A (en) * 1986-11-20 1990-07-10 University Patents, Inc. Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency
US5559038A (en) * 1994-05-04 1996-09-24 The Regents Of The University Of Colorado Gas chromatography/mass spectrometry determination of oxidized sulfhydryl amino acids
US6174696B1 (en) * 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
US6664073B1 (en) * 1999-11-02 2003-12-16 Catch Inc. Enzymatic cycling assays for homocysteine and cystathionine
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
US20060284218A1 (en) * 2003-09-03 2006-12-21 The Regents Of The University Of California Nanoelectonic devices based on nanowire networks
US20100166870A1 (en) * 2006-12-21 2010-07-01 The University Of Western Australia Method for Coating Nanoparticles
CN102150037B (zh) * 2008-07-11 2014-06-04 康奈尔大学 集成电荷传感器的纳米流体通道及基于该纳米流体通道的方法
US20120041274A1 (en) * 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers

Also Published As

Publication number Publication date
US20140045193A1 (en) 2014-02-13
AU2013299409A1 (en) 2015-02-26
WO2014026157A3 (en) 2014-05-08
EP2882862A4 (en) 2016-07-20
WO2014026157A2 (en) 2014-02-13
CA2880928A1 (en) 2014-02-13
EP2882862A2 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
MX2015001788A (es) Metabolitos de metionina predicen la evolución agresiva del cáncer.
PH12016501206A1 (en) The use of inhibitors of bruton`s tyrosine kinase (btk)
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
UA78641U (ru) Способ прогнозирования тяжести больных острым панкреатитом
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.
UA82125U (ru) Способ прогнозирования рефрактур у больных с ложными суставами
UA96067U (uk) Спосіб прогнозування зрощення перелому
UA96073U (uk) Спосіб прогнозування зрощення перелому
UA96011U (uk) Спосіб прогнозування зрощення перелому
UA96013U (uk) Спосіб прогнозування зрощення перелому
UA95590U (uk) Спосіб прогнозування зрощення перелому
UA95973U (uk) Спосіб прогнозування зрощення перелому
UA95662U (uk) Спосіб прогнозування зрощення перелому
UA96076U (uk) Спосіб прогнозування зрощення перелому
UA95972U (uk) Спосіб прогнозування зрощення перелому
UA96515U (uk) Спосіб прогнозування зрощення перелому
UA96111U (uk) Спосіб прогнозування зрощення перелому
UA95587U (uk) Спосіб прогнозування зрощення перелому
UA95937U (uk) Спосіб прогнозування зрощення перелому
UA96069U (uk) Спосіб прогнозування зрощення перелому
UA96926U (uk) Спосіб прогнозування зрощення перелому
UA95567U (uk) Спосіб прогнозування зрощення перелому
UA96045U (uk) Спосіб прогнозування зрощення перелому
UA96046U (uk) Спосіб прогнозування зрощення перелому
UA96126U (uk) Спосіб прогнозування зрощення перелому